Hank T, Sandini M, Ferrone CR, et al. - Through a cohort study of 346 patients who were receiving neoadjuvant therapy (NAT) of overall 753 individuals with resected pancreatic cancers, experts contrasted postoperative complications in patients who underwent either upfront resection or pancreatectomy after NAT, focusing on clinically relevant postoperative pancreatic fistula (CR-POPF) and potential relationships with overall survival. Neoadjuvant therapy could be related to an important decrease in the rate of CR-POPF. Moreover, standard factors correlated with CR-POPF seemed to be no longer applicable after NAT. Nevertheless, once CR-POPF had occurred, it was related to a notable decline in long-term survival. Patients with CR-POPF may need closer follow-up and could profit from additional therapy.